FibroFind, based in Newcastle, United Kingdom, is a globally recognised pre-clinical contract research organisation with patented Precision Cut Tissue Slice ("PCTS") platform revolutionising drug testing and pre-clinical research. The partnership between Vespa and FibroFind will seek to advance the PCTS platform into new tissue types and expand the use cases further across pre-clinical testing and drug discovery offering to a rapidly growing global market.
The BDO financial and tax due diligence team were excellent to work with. They were proactive, responsive and had a high attention to detail. In addition, the team’s sector experience was tremendously helpful in strengthening Vespa Capital’s understanding of the key underlying drivers of financial performance. I would thoroughly recommend this team.
David Forbes, Partner, Vespa Capital LLP
It has been a pleasure supporting Vespa Capital with their investment, as well as getting to know the FibroFind team and business. This transaction was a great opportunity to utilise our existing sector expertise within Life Sciences and Healthcare, as well as learning about a unique and current edge offering. We look forward to seeing FibroFind continue to grow and succeed following this investment.
Lewis Winston, Director, Life Sciences and Healthcare Transaction Services
The BDO Project Team Included:
Transaction Services: Graeme Hurst, Lewis Winston, Taylor Pearce, Miles Devereux, Daanyaal Khokhar
Tax: Sam Boundy, Will Searle, Amy Hoare, Ausaf Khan